» Chordate accelerates its global market establishment
» Strong momentum for Curasight in the first half of 2022
» Miri's CEO on sales growth and market expansion
» CLS CEO on the issue and upcoming FDA announcement
» Mendus well positioned for clinical progress
Read BioStock's newsletter for v.34 here.
Morning news
Vicore Pharma provides an update on the phase II AIR trial in idiopathic pulmonary fibrosis. Read more.
Erik Penser Bank begins monitoring of Idogen. Read more.
Biosergens The board of directors decides on a rights issue of approximately SEK 60,2 million. Read more.
Shareholders in Ray Intelligence proposes that the extraordinary general meeting resolves to acquire all shares in Innowearable. Read more.
Company reports:
Summons:
Change in the number of votes and equity:
Genmab Lytix Biopharma Orion Pihlajalinna Revenio Group Stayble Therapeutics
News since Thursday lunch
Xintelas subsidiary Targinta has presented new preclinical data for the toxin-armed antibody TARG9. Read more.
Modus Therapeutics announced that the first patient has been enrolled in a phase I study evaluating sevuparin in pediatric patients with severe malaria. Read more.
Klaria Pharma announced that it will present at Erik Penser Banks company day. Read more.
Cereno Scientific announced the completed ownership transaction and agreed subscription commitment. Read more.
BrainCool has published a correction to the latest interim report. Read more.
Peptonic Medical signed distribution agreements with German Medical Supplies concerning the United Arab Emirates. Read more.
Pfizer and BionTech has received a positive opinion on their bivalent, non-micronized booster vaccine against COVID-19. Read more.
BactiQuant announced the results of their private placement. Read more.
Medivir announced that they will present at Pareto Securities Healthcare conference. Read more.
Scandinavian ChemoTech announced changes in management. Read more.
Novo Nordisk has acquired Forma Therapeutics. Read more.
Genetic Analysis appointed Later Corporate Finance as a liquidity guarantor for the company's shares. Read more.
Analyst Group has published an analysis of Aptahem. Read more.
This morning's price development
Winner: ObsteCare 20,3%, Aino Health 19%, AegirBio 15,2%, Pharmiva 15,1%, Phase Holographic 14,8%
Förlorare: IRRAS -41,4%, Lipum -12,5%, Isofol Medical -9%, Luxbright -8%, I-Tech -6,1%
Index: OMXS 1 891%, Healthcare -0,87